Chiou et al. demonstrated that co-expression of Oct4 and Nanog in A549 lung adenocarcinoma cells led to an augmentation of the CD133+ subpopulation, intensifying their capabilities in EMT, drug resistance, and tumor initiation [150]. Here, NANOG is linked to neoplasm.